Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery

Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise,
Inc. today announced the formation of a strategic alliance that offers
clients access to Atomwisea??s artificial intelligence (AI)-powered,
structure-based, drug design technology, which allows scientists to
predict how well a small molecule will bind to a target protein of
interest. By removing sole reliance on empirical screening, AI enables
drug researchers to test an extremely large and diverse chemical space
in a matter of days and move through the optimization process quickly by
focusing only on those compounds predicted to have improved
target-binding attributes.

This press release features multimedia. View the full release here:

This alliance combines two industry-leading drug discovery platforms:
Atomwisea??s AI technology and Charles Rivera??s unique portfolio of
end-to-end drug discovery and early-stage development capabilities and
expertise. Leveraging Atomwisea??s AI technology and Charles Rivera??s
integrated drug discovery platform has the potential to significantly
streamline the hit discovery, hit-to-lead, and lead optimization process
for clientsa?? research efforts.

Through the collaboration, Charles River will have access to Atomwisea??s
AI technology to use with their existing portfolio of drug discovery
services. Atomwisea??s patented technology can analyze billions of
compounds and screen challenging target proteins in the small molecule
drug discovery process. The advantages of Atomwisea??s AI technology will
provide Charles Rivera??s clients with the opportunity to efficiently
screen billions, and evaluate thousands, of compounds to optimize
potency, selectivity, and toxicity during hit and lead identification
before committing resources to assays or syntheses.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июнь 2019    »